title: [Combined treatment of acute ischemic syndrome].
abstract: Lots of changes has been made on the treatment of ischaemic heart disease (especially the acute ischaemic syndrome) during the last few years. Large scale, multicentre trials provided clinical evidences the novel therapeutical approach of acute coronary syndrome (ACS). In order to suit this great challenge and to treat the patients with ACS successfully, all efforts should be addressed to open the occluded coronary artery, and to restore coronary circulation as soon as possible. During this process the first mandatory step is to perform acute coronarography, in order to reveal the exact pathomorphology, and to make a plan for the optimal treatment. Patients with acute ischaemic syndrome should be transferred to the haemodynamic laboratory within 2-6 hours from the development of the first clinical symptoms, to perform a primary coronary intervention and/or pharmacological treatment when required. A well-established, local/regional system is suitable to organize different levels of medical treatment from the family medicine to the regional heart center, and enables to transfer patients to the appropriate place without delay, and gives an equal chance for every patient with acute ischaemic syndrome.
authors.affiliation: Pécsi Tudományegyetem, Altalános Orvostudományi Kar, Szívgyógyászati Klinika.
authors.forename: Lajos
authors.initials: L
authors.lastname: Papp
authors.forename: Attila
authors.initials: A
authors.lastname: Cziráki
authors.forename: Iván
authors.initials: I
authors.lastname: Horváth
mesh_terms: D000208:Acute Disease; D002317:Cardiovascular Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D006329:Heart Conduction System / Q000503:physiopathology*; D006801:Humans; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D002317:Cardiovascular Agents